Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 7 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 11660330

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    VACCINEX, INC. · Granted May 30, 2023 · Expires May 25, 2043

    granted
  2. US 11654145

    Combination therapy involving diaryl macrocyclic compounds

    TURNING POINT THERAPEUTICS, INC. · Granted May 23, 2023 · Expires May 18, 2043

    granted
  3. US 11655455

    Enhanced systems for cell-mediated oncolytic viral therapy

    Calidi Biotherapeutics, Inc. · Granted May 23, 2023 · Expires May 18, 2043

    granted
  4. US 11648307

    Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

    The Board of Regents of the University of Texas System · Granted May 16, 2023 · Expires May 11, 2043

    granted
  5. US 11648302

    Indoleamine 2,3-dioxygenase based immunotherapy

    IO Biotech ApS · Granted May 16, 2023 · Expires May 11, 2043

    granted
  6. US 11642366

    Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy

    GLYCOMIRA THERAPEUTICS, INC. · Granted May 9, 2023 · Expires May 4, 2043

    granted
  7. US 11642374

    Intracellular genomic transplant and methods of therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 9, 2023 · Expires May 4, 2043

    granted
  8. US 11642375

    Intracellular genomic transplant and methods of therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 9, 2023 · Expires May 4, 2043

    granted
  9. US 11642401

    Activation of resident memory T cells for cancer immunotherapy

    Regents of the University of Minnesota · Granted May 9, 2023 · Expires May 4, 2043

    granted
  10. US 11640848

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  11. US 11638753

    Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

    PDS Biotechnology Corporation · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  12. US 11631483

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted
  13. US 11618784

    Anti-CD47 combination therapy

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Apr 4, 2023 · Expires Mar 30, 2043

    granted
  14. US 11612652

    Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

    PDS Biotechnology Corporation · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted
  15. US 11607557

    Devices and systems for treating pain based on light therapy

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Mar 21, 2023 · Expires Mar 16, 2043

    granted
  16. US 11608367

    Peptides for angiogenic therapy

    The Regents of the University of California · Granted Mar 21, 2023 · Expires Mar 16, 2043

    granted
  17. US 11596694

    Compositions and methods for predicting response to NaPi2b-targeted therapy

    Mersana Therapeutics, Inc. · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  18. US 11596671

    Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression

    Takeda Pharmaceutical Company Limited · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  19. US 11596696

    Combination therapy with an anti-CD25 antibody-drug conjugate

    ADC THERAPEUTICS SA · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  20. US 11591402

    Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy

    The Regents of the University of California · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  21. US 11591579

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    The Board of Regents of the University of Texas System · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  22. US 11583556

    Modified cells and methods of therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  23. US 11576883

    L-DOPA microbiome therapy

    The Board of Regents of the University of Texas System · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  24. US 11578371

    Biomarkers for predicting tumor response to and toxicity of immunotherapy

    MIRA DX, INC. · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted